पैरासिटामोल और कोडीन और नाल्ट्रेक्सोन का इंटरैक्शन

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] .

Patients with current physiologic opioid dependence [see Warnings and Precautions ( 5.3 ) ] .

Patients in acute opioid withdrawal [see Warnings and Precautions ( 5.3 ) ] .

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] .

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics (4) .

Consider recommending or prescribing an opioid overdose reversal agent ( see WARNINGS, Life-Threatening Respiratory Depression ; DOSAGE AND ADMINISTRATION, Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose ).

If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent ( see WARNINGS, Life-Threatening Respiratory Depression ; DOSAGE AND ADMINISTRATION , Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose ).

Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene).

Explain to patients and caregivers that effects of opioid overdose reversal agents like naloxone and nalmefene are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if an opioid overdose reversal agent is administered ( see OVERDOSAGE ) .